We’re testing a new AI assistant to help patients, caregivers, and researchers find information faster. Click the FCF Assistant button in the lower right corner to try it.
Kurt Losert 
A clinical trial of a new combination immune therapy specifically designed for fibrolamellar carcinoma (FLC) is beginning to enroll patients at the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University (Baltimore, MD). The study is led by Drs. Marina Baretti and Mark Yarchoan. Importantly, this trial builds directly on findings from earlier studies that …
Registration is now open for the Patient & Family Gathering to be held on September 18 – 20, 2026, at the Lake Mansfield Trout Club in Stowe, Vermont. This unique event brings together patients, families and caregivers dealing with fibrolamellar, helping them build connections and friendships with others facing similar challenges. Please click here to …
Participation in clinical trials can be critical for fibrolamellar carcinoma patients—but the cost of travel, lodging, and time away from work or school can prevent many from enrolling. FCF is working to reduce these barriers with its Clinical Trial Patient Assistance Program, which provides housing assistance for patients with financial need while they are participating …
A recent article from the University of Wisconsin highlights ongoing progress in fibrolamellar carcinoma (FLC) research led by Dr. Sean Ronnekleiv-Kelly, a surgical oncologist focused on improving outcomes for this ultra-rare liver cancer. Dr. Ronnekleiv-Kelly’s work centers on understanding how these tumors develop and identifying potential treatment targets. His lab studies patient tumors and pre-clinical …
In a recent study funded by FCF, researchers at the University of Washington, Fred Hutchinson Cancer Center, and Cornell University shed important light on why immunotherapy has struggled to work in fibrolamellar carcinoma (FLC). Led by Dr. Venu G. Pillarisetty and Dr. Praveen Sethupathy, a collaborative, multidisciplinary team set out to understand why treatments like …
We are excited to announce the publication of a landmark paper in Nature Medicine highlighting a major advance in targeted immunotherapy for fibrolamellar carcinoma (FLC). The article, A Therapeutic Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma: A Phase 1 Trial, describes a collaborative effort by researchers at the Johns Hopkins University School of Medicine (Baltimore, MD) …
Today, on World Cancer Research Day, we join the global cancer community in recognizing the power of research to transform lives. This year’s theme, “Cancer Research Needs Us All,” resonates with our mission at the Fibrolamellar Cancer Foundation (FCF)—where patients, families, researchers, and supporters unite to accelerate progress against fibrolamellar carcinoma (FLC), a rare and …
As summer heats up, so does FCF’s commitment to fibrolamellar research. We’ve launched our 2025 Summer Appeal and invite you to join our effort to develop more effective treatments for fibrolamellar patients. The Fibrolamellar Cancer Foundation (FCF) is now supporting four groundbreaking clinical trials, an extraordinary milestone for our rare disease community. One of these trials has …
Registration is now open for the Patient & Family Gathering to be held on September 12 – 14, 2025, at the Lake Mansfield Trout Club in Stowe, Vermont. This unique event brings together patients, families and caregivers dealing with fibrolamellar, helping them build connections and friendships with others facing similar challenges. Please click here to …